Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Accumulated Expenses: 2009-2025

Historic Accumulated Expenses for Madrigal Pharmaceuticals (MDGL) over the last 14 years, with Sep 2025 value amounting to $345.4 million.

  • Madrigal Pharmaceuticals' Accumulated Expenses rose 163.64% to $345.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $345.4 million, marking a year-over-year increase of 163.64%. This contributed to the annual value of $124.7 million for FY2024, which is 38.58% up from last year.
  • Madrigal Pharmaceuticals' Accumulated Expenses amounted to $345.4 million in Q3 2025, which was up 119.32% from $157.5 million recorded in Q2 2025.
  • Over the past 5 years, Madrigal Pharmaceuticals' Accumulated Expenses peaked at $345.4 million during Q3 2025, and registered a low of $44.1 million during Q1 2021.
  • Its 3-year average for Accumulated Expenses is $130.0 million, with a median of $115.6 million in 2024.
  • Per our database at Business Quant, Madrigal Pharmaceuticals' Accumulated Expenses declined by 1.62% in 2023 and then surged by 163.64% in 2025.
  • Madrigal Pharmaceuticals' Accumulated Expenses (Quarterly) stood at $55.0 million in 2021, then surged by 66.15% to $91.5 million in 2022, then dropped by 1.62% to $90.0 million in 2023, then spiked by 38.58% to $124.7 million in 2024, then spiked by 163.64% to $345.4 million in 2025.
  • Its Accumulated Expenses was $345.4 million in Q3 2025, compared to $157.5 million in Q2 2025 and $124.2 million in Q1 2025.